Innate Pharma S.A. (IPHA) Stock Score, Valuation & Financial Research
Innate Pharma S.A. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 17/100.
Quick answer for IPHA
Innate Pharma S.A. currently has a Wall Street Score of 17/100. The stored market price is $1.87. Its financial score is 8/100. Its valuation score is 0/100. The latest WSS change is -1.3 points. These figures are a research snapshot, not a buy or sell recommendation.
What Innate Pharma S.A. does
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous
IPHA financial snapshot
- Wall Street Score:
- 17/100
- Current price:
- $1.87
- Market capitalization:
- $175.6M
- Revenue:
- $17.8M
- Net income:
- $-113.5M
- Free cash flow:
- $-40.3M
- Cash:
- $32.4M
- Total debt:
- $26.0M
- EPS:
- -0.61
- Financial score:
- 8/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is +4.5%.
- Free cash flow is $-40.3M, showing cash burn in the current stored period.
- The balance sheet shows $32.4M of cash versus $26.0M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -1.3 points: IPHA decreased 1.3 points because Debt declined by 10 points, Asset declined by 2.6 points, Buffett declined by 3 points.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 8/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research IPHA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.